Pharming Group N.V. (PHAR)
| Market Cap | 844.80M |
| Revenue (ttm) | 226.46M |
| Net Income (ttm) | 40.29M |
| Shares Out | 64.00M |
| EPS (ttm) | 0.59 |
| PE Ratio | 22.55 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $13.20 |
| Previous Close | $12.60 |
| Change ($) | 0.60 |
| Change (%) | 4.78% |
| Day's Open | 12.84 |
| Day's Range | 12.98 - 13.50 |
| Day's Volume | 5,633 |
| 52-Week Range | 12.24 - 21.99 |
Pharming Group N.V. (Euronext Amsterdam: PHARM) announces that, effective today, its American Depositary Shares ("ADSs") have been admitted for listing on the Nasdaq Global Market ("Nasdaq") under the s...
Pharming Group N.V., a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical...
Pharming Group N.V. has filed to go public with an IPO on the NASDAQ.
About PHAR
Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated ... [Read more...]
| Industry Research and Development in Biotechnology | Founded 1988 |
| CEO Sijmen de Vries | Employees 262 |
| Stock Exchange NASDAQ | Ticker Symbol PHAR |
Financial Performance
In 2020, Pharming Group's revenue was 185.69 million, an increase of 9.86% compared to the previous year's 169.02 million. Earnings were 33.04 million, a decrease of -8.73%.